Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Total Debt (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Total Debt for 11 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Total Debt changed 0.12% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, changed 0.12% year-over-year, with the annual reading at $1.0 billion for FY2025, 0.12% changed from the prior year.
  • Total Debt for Q4 2025 was $1.0 billion at BeOne Medicines, down from $1.6 billion in the prior quarter.
  • The five-year high for Total Debt was $1.6 billion in Q3 2025, with the low at $209.1 million in Q4 2022.
  • Average Total Debt over 5 years is $787.2 million, with a median of $646.3 million recorded in 2021.
  • The sharpest move saw Total Debt crashed 66.78% in 2022, then surged 323.62% in 2023.
  • Over 5 years, Total Debt stood at $629.7 million in 2021, then plummeted by 66.78% to $209.1 million in 2022, then surged by 323.62% to $886.0 million in 2023, then rose by 14.9% to $1.0 billion in 2024, then grew by 0.12% to $1.0 billion in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $1.0 billion, $1.6 billion, and $954.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.